Physical stabilization of norwalk virus-like particles

Journal of Pharmaceutical Sciences

Volumn 97, Issue 10, 2008, Pages 4208-4218

  Kissmann, Julian ^a   Ausar, Salvador F ^a,c   Foubert, Thomas R ^b   Brock, Julie ^a   Switzer, Mary H ^b   Detzi, Edward J ^b   Vedvick, Thomas S ^b   Middaugh, C Russell ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b LigoCyte Pharmaceuticals Inc   (United States)

^c Sanofi Pasteur   (Canada)

Author keywords

Calorimetry (DSC); Circular dichroism; Excipients; Fluorescence spectroscopy; Physical stability; Preformulation; Protein aggregation; Protein formulation; Vaccines

Indexed keywords

CHITOSAN; EXCIPIENT; SUCROSE; TREHALOSE; VIRUS VACCINE;

ARTICLE; CIRCULAR DICHROISM; DIFFERENTIAL SCANNING CALORIMETRY; NOROVIRUS; TEMPERATURE STRESS; THERMOSTABILITY; VIRUS LIKE AGENT; VIRUS MORPHOLOGY;

EID: 55749092786     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21315     Document Type: Article

References (29)

1. Glass RI, Noel J, Ando T, Fankhauser R, Belliot G, Mounts A, Parashar UD, Bresee JS, Monroe SS. 2000. The epidemiology of enteric caliciviruses from humans: A reassessment using new diagnostics. J Infect Dis 181:S254-S261.
2. Mead PS, Slutsker L, Dietz V, McCaig LF, Bresee JS, Shapiro C, Griffin PM, Tauxe RV. 1999. Food-related illness and death in the United States. Emerg Infect Dis 5:607-625.
3. Goodgame R. 2006. Norovirus gastroenteritis. Curr Gastroenterol Rep 8:401-408.
4. Hutson AM, Atmar RL, Estes MK. 2004. Norovirus disease: Changing epidemiology and host susceptibility factors. Trends Microbiol 12:279-287.
5. Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. 1999. X-ray crystallographic structure of the Norwalk virus capsid. Science 286:287-290.
6. Bertolotti-Ciarlet A, Crawford SE, Hutson AM, Estes MK. 2003. The 3( end of Norwalk virus mRNA contains determinants that regulate the expression and stability of the viral capsid protein V P1: A novel function for the VP2 protein. J Virol 77:11603-11615.
7. Jiang X, Wang M, Graham DY, Estes MK. 1992. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 66:6527-6532.
8. Yoda T, Terano Y, Shimada A, Suzuki Y, Yamazaki K, Sakon N, Oishi I, Utagawa ET, Okuno Y, Shibata T. 2000. Expression of recombinant Norwalk-like virus capsid proteins using a bacterial system and the development of its immunologic detection. J Med Virol 60:475-481.
9. Xia M, Farkas T, Jiang X. 2007. Norovirus capsid protein expressed in yeast forms virus-like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts. J Med Virol 79:74-83.
10. Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. 1996. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci USA 93:5335-5340.
11. Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, Estes MK. 2001. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol 75:9713-9722.
12. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. 2003. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 108:241-247.
13. Ault KA. 2006. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: A review. Obstet Gynecol Surv 61:S26-S31.
14. Young KR, McBurney SP, Karkhanis LU, Ross TM. 2006. Virus-like particles: Designing an effective AIDS vaccine. Methods 40:98-117.
15. Quan FS, Huang C, Compans RW, Kang SM. 2007. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 81:3514-3524.
16. Gomez-Gutierrez J, Rodriguez-Crespo I, Gonzalez-Ros JM, Ferragut JA, Paul DA, Peterson DL, Gavilanes F. 1992. Thermal stability of hepatitis B surface antigen S proteins. Biochim Biophys Acta 1119:225-231.
17. Shank-Retzlaff ML, Zhao Q, Anderson C, Hamm M, High K, Nguyen M, Wang F, Wang N, Wang B, Wang Y, Washabaugh M, Sitrin R, Shi L. 2006. Evaluation of the thermal stability of Gardasil. Hum Vaccin 2:147-154.
18. Volkin DB, Burke CJ, Sanyal G, Middaugh CR. 1996. Analysis of vaccine stability. Dev Biol Stand 87:135-142.
19. Ausar SF, Foubert TR, Hudson MH, Vedvick TS, Middaugh CR. 2006. Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature. J Biol Chem 281:19478-19488.
20. Fan H, Kashi RS, Middaugh CR. 2006. Conformational lability of two molecular chaperones Hsc70 and gp96: Effects of pH and temperature. Arch Biochem Biophys 447:34-45.
21. Kueltzo LA, Ersoy B, Ralston JP, Middaugh CR. 2003. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: A bGCSF case study. J Pharm Sci 92:1805-1820.
22. Ausar SF, Espina M, Brock J, Thyagarayapuran N, Repetto R, Khandke L, Middaugh CR. 2007. High-throughput screening of stabilizers for respiratory syncytial virus: Identification of stabilizers and their effects on the conformational thermostability of viral particles. Hum Vaccin 3:94-103.
23. Jiang G, Joshi SB, Peek LJ, Brandau DT, Huang J, Ferriter MS, Woodley WD, Ford BM, Mar KD, Mikszta JA, Hwang CR, Ulrich R, Harvey NG, Middaugh CR, Sullivan VJ. 2006. Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharm Sci 95:80-96.
24. Peek LJ, Brandau DT, Jones LS, Joshi SB, Middaugh CR. 2006. A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine. Vaccine 24:5839-5851.
25. Chakravarty S, Hutson AM, Estes MK, Prasad BV. 2005. Evolutionary trace residues in noroviruses: Importance in receptor binding, antigenicity, virion assembly, and strain diversity. J Virol 79:554-568.
26. Evans RK, Nawrocki DK, Isopi LA, Williams DM, Casimiro DR, Chin S, Chen M, Zhu DM, Shiver JW, Volkin DB. 2004. Development of stable liquid formulations for adenovirus-based vaccines. J Pharm Sci 93:2458-2475.
27. Lee JC, Timasheff SN. 1981. The stabilization of proteins by sucrose. J Biol Chem 256:7193-7201.
28. Shimizu S, Smith DJ. 2004. Preferential hydration and the exclusion of cosolvents from protein surfaces. J Chem Phys 121:1148-1154.
29. Kendrick BS, Chang BS, Arakawa T, Peterson B, Randolph TW, Manning MC, Carpenter JF. 1997. Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: Role in restricted conformational mobility and compaction of native state. Proc Natl Acad Sci USA 94:11917-11922.